

Fourth Global Steering Committee Meeting of the Global Framework for the progressive control of Transboundary Animal Diseases (GF-TADs GSC4)

18-19 October 2011

FAO Headquarters Rome (Italy)














RVF activities













Network of sentinel herds for the monitoring of RVF in West Africa






RVFV activity in Senegal and Mauritania, 1987- 2008











- -A total of 63 human RVF cases, including 13 fatal cases, was officially reported
- -Camel undoubtedly played an important role in the outbreak












Serodetection 2009 (camels)

Area C.imicola (GCP-RAB-002-FRA)

IgM/IgG seroprevalence:

- 33% in camels and
- 44% in small ruminants



Bezeid Ould Mamy, 2011, EID





U.N. Central Emergency and Rehabilitation Fund (CERF)

850 k\$ (FAO, WHO, UNICEF) incl. 290 for the animal side

- Support to the REMEMA (surveillance network)
- Support to the lab
- Training, education, awareness
- Epi investigation



Awarness and education campaign in Mauritania, 2011, Moughataa of Ouadane with the support of local NGO - delivering the messages to the children in the school is way to touch remote breeder families






























Primary areas

WORLDCLIM rainfall mean (high) -1 Daytime LST annual phase (late) - 2 **Digital Elevation Model** WORLDCLIM rainfall tri-annual phase CMORPH rainfall mean Daytime LST annual amplitude Night-time LST maximum (Low) - 3 Daytime LST tri-annual phase EVI tri-annual phase WORLDCLIM rainfall tri-annual phase


Kappa: 0.985 for 100 bootstraps











0.0

0.2 0.3

0.4

0.5

0.6







- Together with Wageningen University and Research Center in the Netherlands - under the umbrella of GF-TADs - technical support from OIE, WHO and IAEA
- 25 foremost scientists in this highly specialized field, the EU, USDA, GALVmed and the pharmaceutical industry
- To review the **development** status of **candidate** RVF vaccines, the requirements they should meet, **standardization** of challenge models, how to ensure that candidate vaccines reach **market stage**, the need for **vaccine banks**, protection of persons as risk etc.





RIFT VALLEY FEVER VACCINE DEVELOPMENT,

PROGRESS AND CONSTRAINTS

GF-TADs meeting November 2010



